Axim Biotechnologies Inc (AXIM)

[Devolution]

Clinical Laboratory Improvement Amendment waivers would be a whole new ballgame.

Such a waiver would make it so much easier to get the Axim platform of rapid result DED tests into even the smallest of ophthalmology offices.

I'm guessing the Versea/Axim teams can get that waiver approval by about the middle of 2023 (6 months or so from now).

Ordinarily, such an FDA approval would give a stock a nice bump upwards, but with Axim, you never know.

By the time they get the CLIA Waiver, Versea/Axim should have all the bugs worked out with the DED Diagnostic platform and their sales pitch perfected.

Six months later, by the end of 2023, hopefully most who have stayed on this (one way) rollercoaster ride will be back in the black and starting to see the light at the end of the tunnel.

Perhaps by the end of 2024, with the return to the fundamental values of the Constitution firmly re-established and the Republican/Conservative GOP (Good Ole' Party) now renamed the Patriot WTP (We The People) Party (The Meek shall inherit the earth, in its most literal sense), Versea/Axim will have taken advantage of the renewed economic growth expansion and firmly established itself (themselves) as a MAJOR player in the DED diagnostic market.

Would be nice to see Axim hitting a billion dollar market cap and trading at $4 to $5 a share sometime in mid to late 2025.

Godspeed.